
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is well-positioned with a strong product pipeline, significant market potential, and a promising anti-VEGF drug in TH103. However, it will need to manage competition and navigate potential financial risks to fully capitalize on its potential and achieve success in the market. Continued success in clinical trials and strategic partnerships could further drive the company's value and stock price in the long term.
Bears say
Kalaris Therapeutics is highly dependent on the success of TH103 and ADVM-022, with potential competition from existing treatments in the $15 billion market for wet AMD. The company's Outperform rating and $17 price target reflect positive clinical trial results for TH103 and the potential for expansion into other retinal diseases, but the risks and uncertainties in the development and approval process must also be considered. Additionally, the company's gene therapy, ADVM-022, is not scheduled for Phase 3 testing until 2027, which may make it difficult to compete with established treatments in the market.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares